HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A malignant eccrine poroma responds to isotretinoin (13-cis-retinoic acid).

Abstract
In treating a patient with a malignant eccrine poroma, in-vitro studies suggested resistance to dactinomycin and doxorubicin. A trial of weekly 5-fluorouracil produced no response. Likewise, a cycle of cisplatinum and cytarabine was associated with continued progression of the disease. Use of 13-cis retinoic acid induced a partial remission that lasted for 8 weeks with minimal toxicity. The mechanism of action is not known, but local tumor necrosis with sparing of the adjacent normal tissue suggests high specificity.
AuthorsM Roach 3rd
JournalAnnals of internal medicine (Ann Intern Med) Vol. 99 Issue 4 Pg. 486-8 (Oct 1983) ISSN: 0003-4819 [Print] United States
PMID6312862 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Tretinoin
  • Isotretinoin
Topics
  • Adenoma, Sweat Gland (drug therapy, surgery)
  • Antineoplastic Agents (administration & dosage)
  • Drug Therapy, Combination
  • Humans
  • Isotretinoin
  • Lung Neoplasms (secondary)
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local (drug therapy)
  • Neoplasms, Multiple Primary
  • Sweat Gland Neoplasms (drug therapy, surgery)
  • Thigh
  • Tretinoin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: